

7 April 2023

Re: Invitation for public comments on applications to the 24th WHO Expert Committee on Selection and Use of Essential Medicines

COMMENT

The International Society of Paediatric Oncology (SIOP) would like to express support of the following applications submitted by the European Society for Paediatric Oncology (SIOP Europe):

- **I.1** Cancer medicines for children - anaplastic large cell lymphoma – EMLc
- **I.2** Cancer medicines for children - Langerhans cell histiocytosis - EMLc
- **I.8** Rituximab - Burkitt lymphoma - EMLc

These medicines and indications are increasingly relevant and needed globally, including in Member States engaged in the WHO Global Initiative for Childhood Cancer that are strengthening their childhood cancer programs.

SIOP would like to stress the importance of the availability of these medicines for the proposed indications as standard of care, so that evidence for their safety and efficacy can be further developed through clinical research in low-and-middle-income countries (LMICs) and inequalities in access can be addressed.

ABOUT

The **International Society of Paediatric Oncology (SIOP)** is the only global organization representing multidisciplinary healthcare professionals entirely devoted to paediatric and adolescent cancer and a Non-State Actor in Official Relations with the World Health Organization (WHO).

SIOP's Continental Branches span all global regions: SIOP Africa - SIOP Asia - SIOP Europe - SIOP Latin America - SIOP North America - SIOP Oceania

<https://siop-online.org/>

